文献速递肿瘤 PET/CT核素与放射性配体治疗

FDG-PET在CD3-CD20双特异性抗体治疗的复发/难治性大B细胞淋巴瘤中的预后价值:一项多中心分析

Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-01

本研究评估了纵向FDG-PET参数在复发/难治性大B细胞淋巴瘤(LBCL)患者接受CD3-CD20双特异性抗体(BsAbs)治疗中的预后价值。58例有基线PET和45例(78%)有BsAb启动后首次PET的患者纳入分析。基线全身MTV>504.7 cm³与更短的中位PFS相关(1 vs. 3个月,HR=5.6,P=0.00025);首次随访时DS4-5与更高的进展风险(HR=11.42,P=0.0182)和更短生存(HR=7.07,P=0.059)相关;SUVmean降低未达≥75.5%显著增加PFS(HR=7.65,P=0.0065)和OS事件(HR=11.1,P=0.001)风险。纵向半定量PET评估可识别高复发风险患者,可能增强风险分层和个体化管理。

要点

  • 基线全身MTV>504.7 cm³与更短中位PFS相关(1 vs. 3个月,HR=5.6,P=0.00025)。
  • 首次随访DS4-5与更高进展风险相关(HR=11.42,P=0.0182)。
  • SUVmean降低未达≥75.5%显著增加PFS和OS事件风险。

核心结论

  • 纵向半定量PET评估可识别BsAb治疗的复发/难治性LBCL患者中高复发风险者,可能增强风险分层和个体化管理。

研究设计与样本

  • 多中心分析纳入58例有基线PET和45例(78%)有BsAb启动后首次PET的复发/难治性LBCL患者,记录标准PET指标和Deauville评分(DS),随访时百分比变化定义为ΔPET参数,分析DS和半定量PET指标对PFS/OS的预后影响。

主要发现

  • 基线全身MTV>504.7 cm³与更短中位PFS相关(1 vs. 3个月,HR=5.6,P=0.00025;C-index=0.94)。
  • 首次随访DS4-5患者进展风险显著更高(HR=11.42,P=0.0182;C-index=0.97),生存更短(HR=7.07,P=0.059;C-index=0.72)。
  • SUVmean降低未达≥75.5%显著增加PFS事件风险(HR=7.65,P=0.0065;C-index=0.92)和OS事件风险(HR=11.1,P=0.001;C-index=0.95)。

关键数值与推荐

  • 基线全身MTV阈值504.7 cm³用于识别PFS较短的高风险患者。
  • 首次随访DS4-5用于识别进展和生存风险更高的患者。
  • SUVmean降低≥75.5%作为随访时的参考阈值,未达到者PFS和OS事件风险显著增加。

临床怎么用

  • 对BsAb治疗的复发/难治性LBCL患者,可结合基线和随访FDG-PET的半定量参数(MTV、DS、SUVmean变化)进行风险分层。
  • 基线MTV>504.7 cm³或随访DS4-5或SUVmean降低<75.5%提示高风险,可能需加强监测或个体化管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The clinical use of CD3-CD20-directed bispecific antibodies (BsAbs) has significantly improved outcomes of patients with relapsed/refractory LBCL. However, up to 50% of patients relapse. This study evaluated the prognostic value of longitudinal FDG-PET parameters. METHODS: 58 patients with baseline PET and 45 (78%) with first PET after BsAb initiation were included. Standard PET metrics and Deauville score (DS) were recorded, with percent changes at follow-up defined as ΔPET parameters. Prognostic impact of DS and semi-quantitative PET metrics were determined for PFS/OS. RESULTS: At baseline an whole-body MTV > 504.7 cm³ was associated with shorter median PFS of 1 vs. 3 months (HR = 5.6, P = 0.00025; C-index = 0.94). At first follow-up, those with DS4-5 exhibited significantly higher risk of progression (HR = 11.42, P = 0.0182; C-index = 0.97) and shorter survival (HR = 7.07, P = 0.059; C-index = 0.72). Non-achievement of ≥ 75.5% SUVmean reduction significantly increased risk for PFS (HR = 7.65; p = 0.0065; C-index = 0.92) and OS events (HR = 11.1; p = 0.001; C-index = 0.95). CONCLUSION: In summary, longitudinal semi-quantitative PET assessment identified patients at high risk of relapse and may enhance risk stratification and personalized management in BsAb-treated patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wollnitza S, Ventura D, Teichert M, et al. Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis. Eur J Nucl Med Mol Imaging. 2026. PMID: 42223630. doi:10.1007/s00259-026-07958-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。